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Introduction {#s1}
============

Debate continues regarding whether developmental exposure to bisphenol A (BPA) can induce metabolic effects, and results from *in vivo* studies are contradictory. Numerous studies on rodents have reported that developmental exposure to BPA may disturb normal metabolic features, such as early adipogenesis, body weight (BW), lipid levels, liver metabolism, and glucose homeostasis ([@c65]; [@c72]; [@c78]; [@c94]); therefore, BPA has been suggested as a potential obesogen ([@c38]). A few other studies have reported no effects on BW following early exposure to BPA ([@c31]; [@c52]; [@c63]) ([Table 1](#t1){ref-type="table"}).

###### 

Metabolic disturbances observed in animal studies following developmental exposure to bisphenol A.

Table 1 lists studies in the first column; the corresponding doses in micrograms per kilogram, exposure windows, exposure route, strain and species, and their outcomes are listed in the other columns.

  Paper                                         Doses ($\mu g/{kg}$)                Exposure window                                           Exposure route                      Strain, species        Outcomes
  --------------------------------------------- ----------------------------------- --------------------------------------------------------- ----------------------------------- ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ([@c5])                                       0.025, 0.25, 25                     GD8--PND16                                                Osmotic pump                        CD-1 mice              Disrupted global metabolism ($♂$) PND2, 21; significant doses: 0.025, 0.25, $25\;\mu g/{kg}$
                                                1, 10                               Perinatal                                                 Water                               S-D rats               Increased BW and visceral adipose tissue, abnormal lipid levels, lower adiponectin levels; significant doses: 1 and $10\;\mu g/{kg}$
  ([@c23])                                      10                                  GD9--GD16                                                 Subcutaneous                        OF-1 mice              Increased BW and increased weight of fat pad mass increased hepatic triglyceride levels, alterations of mRNA gene expression of genes involved in lipogenesis and liver metabolism ($♂$) PND196; significant dose: $10\;\mu g/{kg}$
  ([@c31])                                      5, 10 ($\mu g/{mL}$)                Embryonic/fetal and throughout lactation                  Water                               ICR mice               No effect on BW ($♂$)
  ([@c48])^a^                                   1, 10 ($\mu g/{mL}$)                GD10--throughout lactation                                Water                               ICR mice               Increased BW ($♀$, $♂$) adipose tissue weight, total cholesterol levels ($♀$) and triacylglycerol levels ($♂$) PND31; significant doses: 1 and $10\;\mu g/{kg}$
  ([@c52])                                      10, 100, 1,000                      Perinatal                                                 Subcutaneous                        CD-1 mice              No effect on BW ($♀$)
  ([@c63])                                      50, 5,000                           Embryonic day 18--21 and PND0--PND7                       i.p to dams, subcutaneous to pups   FCDC rats              No effect on BW, decreased levels of adipoR1, no change in ER1, 2 or $\text{PPAR}\gamma$ levels ($♀$) PND50--60; significant doses: 50 and $5000\;\mu g/{kg}$
  ([@c65])                                      0.25, 2.5, 25, 250                  Perinatal (P) or perinatal and peripubertally ($P + P$)   Osmotic pump                        CD-1 mice              Increased BW (P $♀$ and $P + P\, ♀$) PND28 and 35; elevated insulin levels (P $♀$ and $P + P\, ♀$) PND196 and 238; and elevated glucose levels ($P + P\, ♀$) PND238; significant doses: 0.25 and $2.5\;\mu g/{kg}$
  ([@c67])                                      2, 200                              GD3-PND21                                                 Gavage                              C57/Bl-6 mice          No effect on BW ($♀$, $♂$)
  ([@c66])                                      0.25                                GD1--PND21                                                Diet                                CD-1 mice              Increased BW and length that did not persist throughout adulthood ($♀$, $♂$) PND21; significant dose: $0.25\;\mu g/{kg}$
  ([@c72])                                      70                                  GD6--PND21                                                Water                               S-D rats               Increased BW PND1 ($♀$, $♂$), PND21 ($♀$); increased pWAT and BAT mass, adipocyte hypertrophy and alterations of mRNA gene expression of genes involved in metabolism and lipogenesis PND21($♀$); significant dose: $70\;\mu g/{kg}$
  ([@c78])                                      10, 10,000                          Perinatal                                                 Diet                                C57BL/6 mice           Decreased BW PND1; increased BW, higher body fat content, and impaired glucose homeostasis ($♂$) PND98--117; significant dose: $10\;\mu g/{kg}$
  ([@c83])                                      0.25, 2.5, 25, 250                  Perinatal                                                 Osmotic pump                        S-D rats               Metabolic changes in liver and serum composition ($♀$, $♂$) PND21, 50, 90, 140 and 200; significant doses: 0.25, 2.5, 25, and $250\;\mu g/{kg}$
  ([@c87])[^*b*^](#t1n2){ref-type="table-fn"}   3, 10, 30, 100, 300, 1,000, 3,000   Gestation and lactation                                   Diet                                Hybrid C57BL/6J mice   Increased ($♂$) and decreased ($♀$) BW, decreased fat pad weights, adipocyte size (increased in $♂$, not dose-dependent), and levels of serum triglycerides, leptin, and adiponectin ($♀$) PND147 (effects were dose-dependent)
  ([@c94])                                      50, 250, 1,250                      GD0--PND21                                                Oral gavage                         Wistar rats            Increased body fat percentage ($♀$, $♂$), increased levels of triglycerides and size of adipocytes ($♂$) PND189; significant dose: $50\;\mu g/{kg}$
  This study                                    0.5, 50                             GD3.5--PND22                                              Water                               F344 rats              No effect on BW. Increased plasma triglycerides, adipocyte density (decreased adipocyte size), and alterations of mRNA expression of genes involved in lipogenesis, adipocyte adiponectin signaling, and liver metabolism (e.g, increased levels of adipoR1, no change in ER1, 2, or $\text{PPAR}\gamma$ levels) ($♀$, $♂$) PND22; significant doses: 0.5 and $50\;\mu g/{kg}$

Note: Adipor1, adiponectin receptor 1; BAT, brown adipose tissue; BW, body weight; ER, estrogen receptor; FCDF, Fischer CDF; F344, Fischer 344; GD, gestational day; i.p, intraperitoneal; OF-1, Oncins France 1; PND, postnatal day; PPARγ, peroxisome proliferator-activated receptor gamma; pWAT, perigonadal adipose tissue; S-D, Sprague-Dawley. Significant doses are statistically significant changes compared with controls.

Animals were challenged with a high-fat diet or fructose.

The benchmark dose approach was used in this study.

BPA is used in the manufacturing of many products, including polycarbonate and epoxy plastic food packaging material, and it has been shown that BPA leaches from containers into foodstuff ([@c68]; [@c88]). Geens et al. ([@c24]) estimated a daily human exposure level of $0.1–5\;\mu g/{kg}\,\text{bw}/\text{d}$ from dietary and nondietary sources. Recently, LaKind and Naiman ([@c37]) estimated a median daily intake of $25\;{ng}/{kg}/\text{d}$ for the general U.S. population in 2011--2012, and Covaci et al. ([@c14]) reported estimated geometric mean intakes of $32–41\,\text{ng}/{kg}/\text{d}$ and $18–40\,\text{ng}/{kg}/\text{d}$ for children and their mothers, respectively, from six European countries. ([@c14]; [@c37]). Several studies have revealed measurable urinary BPA concentrations in $\geq 90\%$ of humans in numerous different countries throughout the world ([@c6]; [@c26]; [@c37]; [@c100]).

BPA is an endocrine disruptor with the capacity to bind to several receptors ([@c9]) and has been reported to act as a selective estrogen receptor modulator (SERM), meaning that BPA can execute other modes of action than through classical estrogenic pathways, and, additionally, signaling may vary across different cell types and tissues ([@c50]). BPA interacts with both membrane-bound and nuclear estrogen receptors (ERs), and it also activates nongenomic ER pathways ([@c89]) and further it binds to the orphan receptor human estrogen-related receptor gamma, $\text{ERR}\gamma$, with high affinity ([@c79]). Although BPA was previously believed to be a weak estrogen, more recent studies reveal that in certain contexts, BPA is a potent ER activator ([@c1]; [@c96]). Further, BPA has been shown to be a weak thyroid hormone receptor antagonist in Sprague Dawley^TM^ (S-D) rats exposed to BPA during pregnancy and lactation ([@c101]); it also has anti-androgenic and aromatase inhibiting properties and binds to the aryl hydrocarbon receptor (AhR) in a human breast cancer cell line ([@c3]). AhR is also involved in cross-talk with several other endocrine receptor types ([@c60]). The fact that BPA was originally considered a solely estrogenic compound limited which end points were studied, concentrating on, for example, uterotrophic response ([@c44]; [@c69]). At the present time, other end points are being included, better reflecting the ability of BPA to affect various cell signaling pathways. An analysis of ToxCast™ data used to screen and prioritize 309 environmental chemicals for their potential to act as endocrine disruptors ranked BPA as having the third-highest Toxicological Priority Index (ToxPi), reflecting its capacity to interfere with several different signaling systems ([@c61]).

Sex-specific effects of BPA exposure have been reported in both epidemiological and experimental studies ([@c8]). One example of a study that showed evident sex-specific differences is that by van Esterik et al. (2014), in which hybrid mice (C57BL/6JxFVB) were prenatally exposed to BPA. A dose-dependent increase in body and liver weight was reported in adult male offspring, whereas a dose-dependent decrease in body and liver weight was seen in female offspring, suggesting that BPA can program different metabolic phenotypes in male and female mouse offspring.

During development, hormones in minute concentrations (pico- to nanomolar) regulate the differentiation and growth of cells, and this delicate regulation may thus be sensitive to disruption by endocrine active compounds. What should be considered low-dose exposure to endocrine-disrupting compounds has been debated, sometimes defined as below the lowest-observed-adverse-effect-level (LOAEL), the no-observed-adverse-effect-level (NOAEL), or tolerable daily intake (TDI), but is now more often defined as environmentally relevant levels ([@c91]), that is to say, the level of the specific compound to which the population is generally exposed. In 2015, the TDI of BPA was reduced by the European Food Safety Authority (EFSA) from $50\;\mu g/{kg}\,\text{BW}/\text{d}$ to a preliminary TDI of $4\;\mu g/{kg}\,\text{BW}/\text{d}$ owing to new data and refined methodologies ([@c19]). However, several low-dose animal studies have reported biological effects of endocrine-disrupting chemicals (EDCs), including BPA, at doses below the current preliminary EFSA TDI. ([@c90]; [@c93]). Hass and colleagues have proposed that the preliminary EFSA TDI of $4\;\mu g/{kg}\,\text{BW}/\text{d}$ may not sufficiently protect humans from endocrine-disrupting effects based on experimental evidence of effects on behavior, early sexual and mammary gland development, and sperm count in rats ([@c12]; [@c27]; [@c42]).

The aim of the present study was to examine the influence of developmental low-dose BPA exposure on adipose tissue and metabolic biomarkers in young Fischer 344 (F344) rats. We used the F344 rat because it may be more sensitive to hormone disruption than the frequently used S-D rat ([@c41]; [@c75]; [@c76]), and we evaluated two exposure doses in the TDI range: $0.5\;\mu g/{kg}\,\text{BW}/\text{d}$, a dose 8--10 times lower than the preliminary EFSA TDI, and a higher dose corresponding to the U.S Food and Drug Administration (FDA) ([@c105]), reference dose (RfD) of $50\;\mu g/{kg}\,\text{BW}/\text{d}$. Outcomes were examined in 5-wk-old female and male F344 offspring, including BW, liver weight, adipose tissue weight, heart weight and heart somatic index (HSI), gene expression, circulating metabolic markers, and adipose and liver tissue morphology.

Materials and Methods {#s2}
=====================

Chemicals {#s2.1}
---------

BPA (CAS 80-05-7, $\left( \text{CH}_{3} \right)_{2}{C\left( C \right.}_{6}H_{4}\left. \text{OH} \right)_{2}$, $\geq 99\%$ purity) (Sigma Aldrich) was dissolved in ethanol (1% of final solution) and diluted with well-flushed tap water to defined concentrations.

Animals and Housing {#s2.2}
-------------------

This study adheres to the ARRIVE guidelines for animal research ([@c34]). The completed ARRIVE guidelines checklist is available upon request from the authors. The Uppsala Ethical Committee on Animal Research approved this study (C26/13) following guidelines laid down by the European Union Legislation ([@c103] and [@c104]). All animals were treated humanely and with regard for alleviation of suffering.

Forty-five time-mated 9-wk-old female F344/DuCrl rats (Charles River) were weighed and chip-marked upon arrival in our laboratory on gestational day (GD)3.5. The study was performed using seven blocks (separated by 1 wk), and all dose groups were equally distributed among blocks. The dams were randomly distributed into three dosing groups \[0 ($n = 18$), 0.5 ($n = 12$) or 50 ($n = 15$) $\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$\], with dams assigned per group aimed at retrieving 12 offspring per dose and sex. The dams arrived during 7 wk, and because some animals were not pregnant (see Table S1), an allocation of animals to groups that were lacking pregnant animals was made, explaining the difference in the number of dams in each dosing group. The manufacturer provided information on the microbiological status of the purchased animals. The rats were kept at an Uppsala University animal facility in enriched polysulfone cages (Euro Standard IV) with glass water bottles to minimize background BPA exposure and were housed in a temperature- ($22 \pm 1{^\circ}C$) and humidity-controlled ($55 \pm 5\%$) room with a 12-h light/dark cycle and air turnover ten times per hour. Dams were randomly assigned to the different treatment groups and were housed one dam per cage. Litters were adjusted to six pups per dam (3 males and 3 females) on PND4. On PND22, the dams were sacrificed, and one male and one female from each litter was selected at random, chip-marked, and moved to a new cage that contained 3 offspring of the same sex and treatment group (each of which had a different mother to avoid litter effects). However, in a few cases, one pup (sibling) not included in the experiment was allocated to the cage to obtain 3 animals per cage. In total, there were 26 control offspring (13 males, 13 females), 21 BPA0.5 offspring (dams exposed to $0.5\;\mu g/{kg}\,\text{BW}/\text{d}$; 11 males, 10 females), and 16 BPA50 offspring (dams exposed to $50\;\mu g/{kg}\,\text{BW}/\text{d}$; 9 males, 7 females). Animals were surveyed on a daily basis. The offspring were weighed at PND22, PND29, and before sacrifice at PND35. Animals were anesthetized using a cocktail of ketamine ($90\;{mg/kg}$) and xylazine ($10\;{mg/kg}$) (intraperitoneal injection) according to Institutional Animal Care and Use Committee anesthesia guidelines for rats ([@c29]). The anogenital distance (AGD) and body length of the offspring were measured, and all animals were sacrificed through aortic exsanguinations. Experiments were carried out during daytime in a dedicated laboratory neighboring the animal facility.

Food and water were available *ad libitum*, and intake was registered per cage. Rats were fed a standard breeding chow \[RM3 (NOVA-SCB)\] until weaning and a maintenance diet \[RM1 (NOVA-SCB)\] after weaning. The manufacturer specified the nutrient and phytoestrogen content of feed provided to the dams and newborn pups \[RME3, batch 9,987: 11.2 and $< 10\;{Mg}/{kg}$ of genistein and daidzein, respectively, and $11.3\;\mu g/g$ total genestein equivalents \[$\text{TGE} = \text{genistein} + \left( \text{daidzein} \times 0.1 \right)$\] and to offspring after PND22 (RME1, batch 1,028: $< 10\;{Mg}/{kg}$ of both genistein and daidzein, and $< 10.1\;\mu g/g$ TGE). All values were well below the Organisation for Economic Co-operation and Development's (OECD's) upper limit. ([@c55]).

Exposure {#s2.3}
--------

To mimic the most likely route of human exposure, dams were exposed to BPA via their drinking water *ad libitum* from GD3.5 until PND22. Consumed water volume was recorded. Control females received water containing 1% ethanol (vehicle). Based on the volume consumed by the dams in our pilot study, we aimed for average doses of $0.5\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$ (denoted BPA0.5) and $50\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{day}$ (denoted BPA50) (see Table S2). The main routes of BPA exposure were via the placenta *in utero* and via lactation. BPA concentrations were verified at the Division of Occupational and Environmental Medicine in Lund, Sweden, using the modified method described in ([@c4]). The division in Lund is a reference laboratory chosen for the European biomonitoring project \[Consortium to Perform Human Biomonitoring on a European Scale (COPHES); <http://www.eu-hbm.info/democophes>\].

Blood and Organ Sampling {#s2.4}
------------------------

Blood and organ samples were collected from 26 control rats (13 males, 13 females), 21 BPA0.5 rats (11 males, 10 females), and 16 BPA50 rats (9 males, 7 females). Blood was collected in ethylenediaminetetraacetic acid (EDTA)/protease inhibitor--treated tubes and centrifuged ($2,500 \times g$,10 min, $4{^\circ}C$) to prepare plasma. Aliquots were stored at $- 20{^\circ}C$ for blood lipid analyses and at $- 70{^\circ}C$ for all other analyses.

Retroperitoneal white adipose tissue (rWAT) was collected from the dorsal wall of the abdominal cavity, and gonadal WAT (gWAT) was collected from areas surrounding the epididymis, testis, and ovary. Inguinal WAT (iWAT) was dissected from the area around the pelvis and from the hind limb thigh. The conflated interscapular brown and white adipose tissues were separated into interscapular brown (iscpBAT) and white (iscpWAT) adipose tissue. Fat depots and liver were weighed, snap frozen in liquid nitrogen, and stored at $- 70{^\circ}C$. The liver somatic index (LSI; $\text{liver}\,\text{weight}/\text{BW} \times 100$), anogenital index \[AGDi; $\text{AGD}/\sqrt[3]{\text{BW}}$ ([@c13])\], and heart somatic index (HSI; $\text{heart}\,\text{weight}/\text{BW} \times 100$) were calculated.

Histological Analysis of Adipose Tissue and Fat Accumulation in Liver {#s2.5}
---------------------------------------------------------------------

To investigate the potential impact of BPA exposure on adipose tissue morphology, sections of gWAT, iWAT, and iscpBAT were analyzed. All analyses in the present study were performed by individuals without knowledge of dosing groups. Frozen sections ($8\;\mu m$ thick) of iWAT, gWAT, iscpBAT, and liver from 36 animals (6 males and 6 females selected at random from each dose group) were cut at two levels with a distance of $300\;\mu m$ using a cryostat (Leica CM1860 UV; Leica Microsystems) and were stained with Oil Red O/hematoxylin. Micrographs were taken of four different areas of each section at 40× magnification using a Leica DMST camera (Leica Microsystems). Adipocyte number in adipose tissue depots and percentage of liver fat were quantified per high power field (HPF) (40× magnification) using the software package Image Processing and Analysis in Java (ImageJ; National Institutes of Health).

RNA Extraction and mRNA Quantification {#s2.6}
--------------------------------------

Total RNA was extracted from adipose tissue and liver samples using the Trizol method (Life technologies/Thermo Fisher) according to the manufacturer's instructions. DNase treatment was performed for all RNA preparations to remove potential contaminating DNA (*Ambion*® DNA-free™ DNAse Treatment and Removal Reagents, Life Technologies). RNA concentration and quality (260/280 ratio $\geq 1.7$) were measured using a Nanodrop™ ND-1000 spectrophotometer (Thermo Scientific).

The liver is a key organ for metabolism and detoxification. Therefore, alterations in the expression of genes involved in liver metabolism were measured using real-time quantitative polymerase chain reaction (RT-qPCR); alterations in gene expression were also measured in adipose tissue. We tested 26 target genes and 2 housekeeping genes. We chose these specific genes for their indicative and representative roles in de novo lipogenesis, beta-oxidation, lipid mobilization, hormonal function, and inflammation. The complete list of gene targets tested in liver and adipose tissue is presented in Table S3. For complementary DNA (cDNA) synthesis, RNA was reverse-transcribed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems) and random hexamer primers. To measure relative transcription levels using RT-qPCR, cDNA samples were loaded in duplicates with SsoFast EvaGreen qPCR Supermix (Bio-Rad) and exon-spanning primers, designed using Universal Probe Assay Design Center (Roche Diagnostics) and pre-validated for optimal efficiency (80--120%) (see Table S4). The RT-qPCR analyses were performed using a BioRad CFX96 Touch Real-Time Detection System (Bio-Rad). Transcriptional levels (Ct values) were normalized against ribosomal protein, large, P0 (*36B4*), and normalized values ($\Delta\text{Ct}$) were subtracted from the mean $\Delta\text{Ct}$ in control groups to acquire a $\Delta\Delta\text{Ct}\,\text{value}$. The logarithmic $\Delta\Delta\text{Ct}$ values were linearized using the $2^{- \Delta\Delta\text{Ct}}$ method ([@c39]). Moreover, the difference between the treatment groups in expression of examined housekeeping genes *36B4* and glucuronidase beta (*Gusb*) was tested statistically to exclude the possibility that the treatment *per se* affected the expression. Overall, *36B4* was the most stable housekeeping gene (females, ${CTRL} = 100 \pm 10.4\%$, $\text{BPA0.5} = 93.6 \pm 12.0\%$, $\text{BPA50} = 98.9 \pm 16.2\%$, $p = 0.9$; males, ${CTRL} = 100 \pm 14.1\%$; $\text{BPA0.5} = 114 \pm 23.8\%$; $\text{BPA50} = 118 \pm 16.5\%$; $p = 0.7$), and further, the amplification of *36B4* exhibited 105.5% efficiency (see Table S4).

Plasma Lipid Analyses {#s2.7}
---------------------

To assess whether BPA exposure affected circulating lipid levels, triglycerides (TGs), adiponectin, leptin, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol were measured in the offspring. Plasma TG and cholesterol analyses were performed using an Architect c8000/c16000 analyzer (Abbott Laboratories) and four different kits: Triglyceride Cat. No. 7D74-21, Cholesterol Cat. No. 7D62-21, LDL-Cholesterol Cat. No. 1E31-20, and HDL-Cholesterol Cat. No. 3K33-21 (Abbott Laboratories) at the Central Clinical Chemistry Laboratory, Uppsala University Hospital, Uppsala, Sweden.

Plasma adiponectin and leptin levels were measured in duplicate by enzyme-linked immunosorbent assay (ELISA) (Rat Total Adiponectin/Acrp30 Quantikine and Mouse/Rat Leptin Quantikine kits; R&D Systems). Intra- and inter-assay precision for leptin were 5.9% and 4.8%, respectively; for adiponectin, intra- and inter-assay precision were 13.1% and 12.5%.

Statistical Analyses {#s2.8}
--------------------

Statistical analyses were performed using STATISTICA 12 (StatSoft Inc.). Males and females were primarily analyzed separately based on the hypothesis that BPA is an endocrine disruptor with likely sex-specific effects. To test this assumption, an interaction term between dose and sex was included. If the interaction term was not significant, we performed a secondary data-driven analysis, merging data from males and females.

Levene's test for homogeneity of variance and the Shapiro--Wilk normality test (SW-W) were performed to determine whether data were normally distributed. Differences between control and exposed groups were evaluated by one-way analysis of variance (ANOVA) if normally distributed, and by the Kruskal--Wallis H (KW-H) test if not. These analyses were followed by Dunnett's or Kruskal-Wallis ANOVA post-hoc tests. Results are expressed as the $\text{mean} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$. A *p*-value of $< 0.05$ was considered to be statistically significant.

Results {#s3}
=======

Body Weight, Weight Gain, Food and Water Intake of Dams during Gestation {#s3.1}
------------------------------------------------------------------------

Weight gain and food and water intake of exposed dams were measured to evaluate whether BPA exposure affected maternal physiology. The average BW of dams at PND22 did not differ significantly between control and BPA-exposed dams. Further, no statistically significant differences were observed between the treatment groups regarding weight gain or food intake. The mean total water consumption was slightly lower for BPA-exposed dams; however, the difference was not statistically significant ($31.9 \pm 0.9\,\text{ml}/d$ compared with $29.8 \pm 0.7\,\text{ml}/d$ BPA0.5: $p = 0.2$) ($31.9 \pm 0.9$ CTRL compared with $29.7 \pm 0.7$ BPA50: $p = 0.2$) (see Table S1). Pups of one BPA0.5 dam were transferred to other BPA0.5 dams at PND4, which explains why $n = 11\,\text{ml}/d$ for this dose group.

Effects on Body and Organ Weights of Offspring {#s3.2}
----------------------------------------------

The number of dams without litters varied among the dose groups, including 4/18, 0/12, and 6/15 in the controls, BPA0.5, and BPA50 groups, respectively, but the pairwise difference was only significant between the two treatment groups (Table S5).

In the primary analysis of outcomes according to sex, there were no significant differences in males or females in the final BW of BPA-exposed offspring compared with controls ([Table 2](#t2){ref-type="table"}). In addition, there were no significant differences in weight gain, BW at PN22, or the weight of the gonadal, inguinal, retroperitoneal, white, or brown interscapular fat pads; nor were there significant differences in AGD, AGDi, LSI, body length, or heart, spleen, or liver weight and liver fat infiltration in female or male offspring ([Table 2](#t2){ref-type="table"}). In males, however, HSI was decreased in BPA0.5-exposed offspring compared with unexposed offspring (ANOVA $p - \text{value} = 0.045$) ($0.443 \pm 0.007$ compared with $0.472 \pm 0.009$, $p = 0.06$); however, the pair-wise comparison (Dunnett's test) was not statistically significant.

###### 

Weight parameters and other measurements in male and female offspring ($mean\pm SE$).

Table 2 lists outcomes in the first column; their corresponding weight compared with controls, 0.5 micrograms BPA concentration per kilograms per day, 50 micrograms BPA concentration per kilograms per day, and ANOVA p values for females and males are listed under other columns.

  Outcome                                      Females                              Males                                                                                                                                                                                                                                                                                           
  -------------------------------------- ------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------- ------------------- ------------------------------------------------------ ----------------------------------------------------- -------------------------------------------
  Number of animals                              13                                   10                                                   7                                                                                                               13                                    11                                                     9                            
  Weaning BW (g)                           $38.8 \pm 0.99$                     $37.9 \pm 1.00$                                      $35.9 \pm 0.67$                    0.2                                                                           $40.8 \pm 0.93$                      $39.1 \pm 0.86$                                        $38.6 \pm 1.50$                    0.7
  Final BW (g)                             $76.8 \pm 1.46$                     $74.9 \pm 1.58$                                      $77.7 \pm 2.81$                    0.6                                                                           $81.0 \pm 1.51$                      $81.1 \pm 2.16$                                        $79.9 \pm 3.18$                    0.9
  Weight gain, wk 3--5 (g)                 $38.0 \pm 0.76$                     $37.0 \pm 1.17$                                      $41.9 \pm 3.13$                    0.1                                                                           $40.2 \pm 1.00$                      $42.0 \pm 1.52$                                        $41.3 \pm 1.86$                    0.6
  Gonadal fat pad (g)                     $0.041 \pm 0.003$                   $0.041 \pm 0.006$                                    $0.047 \pm 0.012$                   0.8                                                                           $0.08 \pm 0.01$                      $0.09 \pm 0.01$                                        $0.09 \pm 0.02$                    0.8
  Inguinal fat pad (g)                     $0.31 \pm 0.02$                     $0.32 \pm 0.02$                                      $0.33 \pm 0.02$                    0.8                                                                           $0.37 \pm 0.02$                      $0.39 \pm 0.02$                                        $0.36 \pm 0.03$                    0.6
  Retroperitoneal fat pad (g)             $0.062 \pm 0.006$                   $0.061 \pm 0.006$                                    $0.048 \pm 0.007$                   0.4                                                                          $0.086 \pm 0.008$                    $0.097 \pm 0.008$                                      $0.075 \pm 0.013$                   0.3
  Interscapular WAT (g)                   $0.086 \pm 0.005$                   $0.101 \pm 0.008$                                    $0.078 \pm 0.007$                   0.08                                                                         $0.086 \pm 0.007$                    $0.100 \pm 0.010$                                      $0.081 \pm 0.017$                   0.5
  Interscapular BAT (g)                   $0.148 \pm 0.005$                   $0.133 \pm 0.012$                                    $0.157 \pm 0.011$                   0.2                                                                          $0.184 \pm 0.009$                    $0.186 \pm 0.009$                                      $0.184 \pm 0.017$                   1.0
  Spleen (g)                              $0.222 \pm 0.006$                   $0.211 \pm 0.006$                                    $0.215 \pm 0.011$                   0.5                                                                          $0.232 \pm 0.005$                    $0.217 \pm 0.009$                                      $0.226 \pm 0.009$                   0.4
  Heart (g)                               $0.361 \pm 0.011$                   $0.332 \pm 0.008$                                     $0.35 \pm 0.011$                   0.2                                                                          $0.382 \pm 0.008$                    $0.358 \pm 0.008$                                      $0.380 \pm 0.016$                   0.2
  HSI                                      $0.47 \pm 0.01$                    $0.443 \pm 0.004$                                     $0.46 \pm 0.01$                    0.2                                                                          $0.472 \pm 0.009$   $0.443 \pm 0.007$[^*a*^](#t2n2){ref-type="table-fn"}   $0.48 \pm 0.014$[^*b*^](#t2n3){ref-type="table-fn"}  0.04[^\*^](#t2n1){ref-type="table-fn"}
  Liver weight (g)                         $3.12 \pm 0.08$                     $3.11 \pm 0.09$                                      $3.19 \pm 0.17$                    0.8                                                                           $3.42 \pm 0.08$                      $3.48 \pm 0.13$                                        $3.28 \pm 0.16$                    0.5
  LSI                                      $4.06 \pm 0.05$                     $4.15 \pm 0.08$                                      $4.10 \pm 0.12$                    0.7                                                                           $4.23 \pm 0.06$                      $4.28 \pm 0.07$                                        $4.10 \pm 0.07$                    0.2
  Liver fat (%)                            $13.9 \pm 4.05$                     $14.9 \pm 3.58$                                      $12.0 \pm 1.92$                    0.8                                                                           $8.85 \pm 1.35$                      $10.3 \pm 2.98$                                        $11.5 \pm 1.33$                    0.6
  Body length (cm)                         $14.8 \pm 0.17$                     $14.9 \pm 0.16$                                      $14.9 \pm 0.23$                    0.9                                                                           $15.5 \pm 0.17$                      $15.4 \pm 0.14$                                        $15.3 \pm 0.21$                    0.6
  AGD (mm)                                 $9.38 \pm 0.34$                     $9.61 \pm 0.25$                                      $9.69 \pm 0.39$                    0.8                                                                           $14.5 \pm 0.42$                      $14.8 \pm 0.40$                                        $14.4 \pm 0.53$                    0.8
  AGDi (${mm}/\sqrt[3]{g\,\text{BW}}$)     $2.20 \pm 0.08$                     $2.28 \pm 0.06$                                      $2.28 \pm 0.10$                    0.7                                                                           $3.35 \pm 0.09$                      $3.41 \pm 0.08$                                        $3.34 \pm 0.10$                    0.8
  HDL (mmol/L)                             $0.77 \pm 0.03$                     $0.80 \pm 0.02$                                      $0.86 \pm 0.02$                    0.3[^*a*^](#t2n2){ref-type="table-fn"}                                        $0.80 \pm 0.04$                      $0.87 \pm 0.03$                                        $0.81 \pm 0.03$                    0.3
  LDL (mmol/L)                            $0.226 \pm 0.007$                   $0.226 \pm 0.013$                                    $0.222 \pm 0.006$                   1.0                                                                          $0.233 \pm 0.007$                    $0.246 \pm 0.008$                                      $0.228 \pm 0.011$                   0.4
  Total cholesterol (mmol/L)               $2.55 \pm 0.1$                      $2.62 \pm 0.06$                                      $2.79 \pm 0.08$                    0.2                                                                           $2.62 \pm 0.09$                      $2.88 \pm 0.05$                                        $2.62 \pm 0.09$                    0.05
  Triglycerides (mmol/L)                   $0.57 \pm 0.03$    $0.77 \pm 0.08$[^*c*^](#t2n4){ref-type="table-fn"}   $0.81 \pm 0.10$[^*d*^](#t2n5){ref-type="table-fn"}  0.02[^\*^](#t2n1){ref-type="table-fn"}[^*e*^](#t2n6){ref-type="table-fn"}     $0.61 \pm 0.04$     $0.81 \pm 0.05$[^*f*^](#t2n7){ref-type="table-fn"}    $0.65 \pm 0.03$[^*g*^](#t2n8){ref-type="table-fn"}   0.008[^\*\*^](#t2n1){ref-type="table-fn"}
  Plasma adiponectin (ng/mL)               $8.95 \pm 7.76$                     $11.02 \pm 1.89$                                     $10.14 \pm 1.11$                   0.5                                                                           $9.60 \pm 0.77$                      $11.92 \pm 0.91$                                      $12.47 \pm 1.60$                    0.1[^*e*^](#t2n6){ref-type="table-fn"}
  Plasma leptin (ng/mL)                    $0.56 \pm 0.09$                     $0.61 \pm 0.10$                                      $0.75 \pm 0.18$                    0.6                                                                           $0.55 \pm 0.11$                      $0.82 \pm 0.09$                                        $0.67 \pm 0.16$                    0.3

Note: AGD, anogenital distance; AGDi, anogenital index; ANOVA, analysis of variance; BAT, brown adipose tissue; BPA, bisphenol A; BW, body weight; HDL, high-density lipoprotein; HIS, heart somatic index; LDL, low-density lipoprotein; LSI, liver somatic index; WAT, white adipose tissue. Animals were exposed to BPA from gestational day (GD)3.5 until weaning at week 3 and were sacrificed at wk 5 (postnatal day 35). Weight gain was recorded from wk 3--5. Dams were dosed with 0.5 or $50\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$ (actual average doses 0.4 and $40\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$, respectively). Control dams were given water with 1% ethanol (vehicle).

CTRL--BPA0.5: $p = 0.06$.

CTRL--BPA50: $p = 0.9$.

CTRL--BPA0.5: $p = 0.1$.

CTRL--BPA50: $p = 0.04$.

Data not normally distributed; Kruskal-Wallis *p*-value (and Kruskal-Wallis post hoc test) shown.

CTRL--BPA0.5: $p = 0.005$.

CTRL--BPA50: $p = 0.8$.

$p < 0.05$; \*\*$p < 0.01$.

Associations between BPA and heart weight and HSI were not significantly different between males and females (interaction $p - \text{values}$ of 0.95 and 0.57, respectively). Therefore, we conducted a secondary analysis of these outcomes for both sexes combined (see Table S6). Heart weight and HSI of BPA0.5-exposed animals (males and females combined) were significantly lower than those of controls (95% and 94% of controls, respectively, both $p = 0.03$, pair-wise comparison; Dunnett's test), but the outcomes were not significantly different from controls for the BPA50 group.

Effects on Plasma Lipids and Adipokines in Offspring {#s3.3}
----------------------------------------------------

On PND35, plasma TG was significantly higher in BPA0.5 males than in controls ($0.81 \pm 0.05\,\text{mmol}/L$ compared with $0.61 \pm 0.04\,\text{mmol}/L$, $p = 0.005$) but was not significantly different in BPA50 males compared with controls ([Table 2](#t2){ref-type="table"} and [Figure 1A](#f1){ref-type="fig"}). In females, plasma TG was significantly higher in BPA50 females than in controls ($0.81 \pm 0.10\,\text{mmol}/L$ compared with $0.57 \pm 0.03\,\text{mmol}/L$, $p = 0.04$) but not in BPA0.5 offspring ([Table 2](#t2){ref-type="table"} and [Figure 1A](#f1){ref-type="fig"}).

![Plasma triglyceride levels and adipocyte density in iWAT of female and male F344 offspring following developmental bisphenol A (BPA) exposure. Effects of developmental exposure to 0.5 (BPA0.5), 50 (BPA50), or $0\,\left( {CTRL} \right)\,\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$; BPA0.5, BPA50, CTRL on **(*A*)** plasma triglyceride levels (mmol/L) in five-wk-old female and male F344 offspring and dams (females, $\mathit{n} = 30$: CTRL, $\mathit{n} = 13$; BPA0.5, $\mathit{n} = 10$; BPA50, $\mathit{n} = 7$); the Kruskal--Wallis test was used to calculate the difference between groups and *p*-values from Dunnett\'s test are shown in the figure (males, $\mathit{n} = 33$: CTRL, $\mathit{n} = 13$; BPA0.5, $\mathit{n} = 11$; BPA50, $\mathit{n} = 9$); analysis of variance (ANOVA)/Dunnett's test was used to calculate the difference between groups and *p*-values from Dunnett\'s test are shown in the figure. **(*B*)** Average number of iWAT fat cells per high power field in female and male F344 offspring \[postnatal day (PND)35\] (females, $\mathit{n} = 18$ CTRL, $\mathit{n} = 6$; BPA0.5, $\mathit{n} = 6$; BPA50, $\mathit{n} = 6$; males, $\mathit{n} = 18$; CTRL, $\mathit{n} = 6$; BPA0.5, $\mathit{n} = 6$; BPA50, $\mathit{n} = 6$), ANOVA/Dunnett's test was used to calculate the difference between groups. Values are shown as the $\text{means} \pm \text{SEM}$. Note: F344, Fischer 344 rat; iWAT, inguinal white adipose tissue. \* $\mathit{p} < 0.05$ \*\* $\mathit{p} < 0.01$.](EHP505_f1){#f1}

Adiponectin and leptin plasma levels were not significantly different from controls in either dose group of males or females ([Table 2](#t2){ref-type="table"}). No significant interaction between sex and dose of BPA was observed regarding adiponectin or leptin ($p > 0.05$ for interaction terms). Therefore, the two sexes were combined in the following analyses.

When both sexes were combined, plasma adiponectin was higher in both dose groups than in controls (124% and 123% higher for BPA0.5 and BPA50, respectively), but the differences were not statistically significant ($p = 0.09$) (see Table S6).

Adipocyte Cell Density {#s3.4}
----------------------

Adipocyte cell density was significantly increased by 121.9% in iWAT of female offspring exposed to BPA0.5 compared with controls ($68.2 \pm 4.4$ number of adipocytes/HPF compared with $55.9 \pm 1.5$ number of adipocytes/HPF, $p = 0.03$). In addition, a 123.2% increase in adipocyte cell density was observed in iWAT of female offspring exposed to BPA0.5 compared with offspring exposed to the BPA50 dose ($68.2 \pm 4.4$ number of adipocytes/HPF compared with $55.3 \pm 2.9$ number of adipocytes/HPF, $p = 0.03$) ([Figure 2A](#f2){ref-type="fig"}). In iWAT of male offspring exposed to BPA50 compared with that in male offspring exposed to BPA0.5, adipocyte cell density was increased by 129.4% ($69.9 \pm 5.1$ number of adipocytes/HPF compared with $54.0 \pm 3.4$ number of adipocytes/HPF, $p = 0.03$) ([Figure 2B](#f2){ref-type="fig"}). However, no such differences were observed between offspring exposed to the BPA50 dose and controls. ([Figure 1B, 2A and 2B](#f1 f2){ref-type="fig"}). There were no significant differences from controls in gWAT or iscpBAT cell density for either dose group in males or females (see Table S7).

![Micrographs of histological sections of iWAT in control and BPA-exposed female and male F344 offspring. Representative histological sections of iWAT from 0.5 (BPA0.5) or 50 (BPA50) $\mu g/{kg}\,\text{BW}/\text{d}$ BPA-exposed female (*A*) and male (*B*) control and BPA-exposed five-wk-old F344 rat offspring. Sections were stained with Oil Red O. Note: F344, Fischer 344 rat; iWAT, inguinal white adipose tissue.](EHP505_f2){#f2}

Gene Transcription in Adipose and Liver {#s3.5}
---------------------------------------

The complete list of gene targets tested in adipose tissue and liver is presented in Table S3. Compared with controls, mRNA expression in gWAT from male offspring was significantly lower in both dose groups for *AdipoR2* and *ACC* and in BPA50 offspring for SCD1, whereas lower expression of *LPL* in both dose groups was significant based on one-way ANOVA only, and a significant one-way ANOVA for *GATA2* reflected significantly lower and higher expression, respectively, in BPA0.5 and BPA50 offspring ([Figure 3A](#f3){ref-type="fig"} and Table S8). In females, mRNA expression in gWAT was significantly higher compared with controls for *AdipoR1* in BPA50 offspring only and significantly lower for *SREBP-1c* in BPA0.5 offspring only, and a significant one-way ANOVA for SCD1 reflected nonsignificant differences in lower and slightly higher expression, respectively, in BPA0.5 and BPA50 offspring ([Figure 3B](#f3){ref-type="fig"} and Table S8). In iWAT, the only significant differences in expression were for lower expression of *AdipoR1* and SCD1f in BPA0.5 males compared with controls ([Figure 3C-D](#f3){ref-type="fig"} and Table S8). Additionally, there were no significant differences in the expression of any genes measured in iscpBAT when evaluated separately in males and females (data not shown).

![Transciptional levels in gWAT and iWAT of female and male F344 offspring following BPA exposure. Effects of developmental exposure to 0.5, 50, or $0\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$ (BPA0.5, BPA50, and CTRL, respectively) in five-wk-old F344 offspring on the relative mRNA expression of **(*A*)** *AdipoR1, AdipoR2, LPL, SCD1, ACC, GATA2* and *SREBP-1c* in male gWAT **(*B*)** *AdipoR1, AdipoR2, LPL, SCD1, ACC, GATA2* and *SREBP-1c* in female gWAT **(*C*)** *AdipoR1* and *SCD1* in male iWAT **(*D*)** *AdipoR1* and *SCD1* in female iWAT (females, $\mathit{n} = 29$: CTRL, $\mathit{n} = 13$; BPA0.5, $\mathit{n} = 10$; BPA50, $\mathit{n} = 6$; males, $\mathit{n} = 32$: CTRL, $\mathit{n} = 12$; BPA0.5, $\mathit{n} = 10$; BPA50, $\mathit{n} = 10$). ANOVA/Dunnett's test was used to calculate the difference between groups. Values are shown as the $\text{means} \pm \text{SEM}$. Note: *ACC*, acetyl-CoAa carboxylase; *AdipoR*, adiponectin receptor (1 and 2); F344, Fischer 344 rat; *GATA2*, G protein-coupled estrogen receptor 1; iWAT, inguinal white adipose tissue; *LPL*, lipoprotein lipase; *SCD1*, stearoyl-CoA desaturase; *SREBP-1c*, sterol regulatory element binding protein-1c. \* $\mathit{p} < 0.05$; \# One-way ANOVA for all groups.](EHP505_f3){#f3}

When males and females were combined, *ACC* and *SREBP-1c* analyzed in gWAT showed significantly lower expression in both dose groups compared with controls, whereas *GATA2* expression was significantly different from controls based on one-way ANOVA ($p = 0.04$), reflecting nonsignificant lower and higher expression, respectively, in BPA0.5 and BPA50 offspring (see Table S6). *Adiponectin* expression was significantly different from controls in iscpBAT from males and females combined, reflecting nonsignificant higher and lower expression, respectively, in BPA0.5 and BPA50 offspring (see Table S6). There were no significant differences in the expression of any key genes in adipogenesis and adipocyte function in gWAT when evaluating males and females together (data not shown).

Expression of only one of the 18 genes examined in liver tissue showed a significant difference based on one-way ANOVA (see Table S8; data not shown for females or for the other genes evaluated in males). Specifically, $\mathit{CEBP\alpha}$ expression was lower in male BPA0.5 and BPA50 offspring than in controls, although the difference was significant only for the BPA50 dose group ($74.9 \pm 4.8\%$, $p = 0.02$).

Discussion {#s4}
==========

The previous BPA TDI of $50\;\mu g/{kg}\,\text{BW}/\text{d}$, which was presumed safe for many years, was based on an NOAEL of $5\;{mg/kg}$ BW/d with a 100-fold uncertainty factor ([@c85]; [@c86]). In January 2015, EFSA reduced the TDI to a preliminary TDI of $4\;\mu g/{kg}\,\text{BW}/\text{d}$ while awaiting data from a long-term study in rats ([@c19]). In the present study, we evaluated developmental exposures of F344 rats to $0.5\;\mu g/{kg}\,\text{BW}/\text{d}$ BPA \[8--10 times lower than the current preliminary EFSA TDI, and consistent with human exposures ([@c10])\] and $50\;\mu g/{kg}\,\text{BW}/\text{d}$ BPA \[corresponding to the former EFSA (see European Food Safety Authority, <http://www.efsa.europa.eu/en/topics/topic/bisphenol>) TDI and the current FDA RfD ([@c105])\], using the oral route of exposure to be consistent with the primary route of BPA exposure in humans ([@c88]). We found that these exposures were associated with significantly higher plasma triglyceride concentrations and iWAT adipocyte cell density in offspring on PND35 depending on the dose and sex of the offspring evaluated. The expression of genes involved in adiponectin signaling and lipid metabolism also differed between exposed offspring and controls depending on the gene, tissue (with most of the differences limited to iWAT), dose, and sex. Finally, when males and females were combined, heart weight and HSI were significantly lower in BPA0.5 offspring, but not BPA50 offspring, than in controls. In the present study, no significant differences in BW were seen in 5-wk-old male and female offspring exposed to BPA during development compared with controls, in accord with previous publications ([@c7]; [@c49]; [@c52]). Others have reported increased ([@c59]; [@c72]) or decreased ([@c51]) BW in different rat strains exposed to low doses of BPA during development.

In the present study, significantly higher plasma triglyceride levels were observed in 5-wk-old BPA50 female and BPA0.5 male offspring than in controls. In experimental studies, elevated triglyceride levels at an early age in animals exposed to environmental endocrine disruptors have been associated with increased BW later in life ([@c53]). In the present study, we did not observe any significant differences in BW in the offspring at 5 wk of age, but we cannot rule out the possibility that differences might have occurred if follow-up had continued. Inconsistencies among studies may reflect differences in animal models, doses, routes of administration, duration of exposures, diets, developmental stage, and sex of the animals, which are all consistent with possible biological differences ([Table 1](#t1){ref-type="table"}). In addition, differences in sample size and power are potential noncausal explanations for differences in findings among different studies. To our knowledge, no one has attempted to reproduce findings for effects of BPA on metabolism using the same experimental model and identical conditions ([Table 1](#t1){ref-type="table"}).

Adipocyte cell density in iWAT (i.e., the number of unilocular cells/HPF) was significantly higher than in controls for female offspring exposed to BPA0.5 but not BPA50 BPA, suggesting adipocyte hyperplasia in response to the lower dose only. In contrast, adipocyte density in males was higher in BPA50 offspring than in BPA0.5 or control offspring (although the difference was significant only between BPA50 and BPA0.5 offspring), suggesting sex-specific differences in effects at a given dose. Adipose tissue expands through an increase in adipocyte cell number (hyperplasia), adipocyte cell size (hypertrophy), or both ([@c30]). It has been suggested that adipocyte hyperplasia occurs only at early developmental stages, implying that the number of adipocytes is programmed during childhood and remains the same throughout the whole lifetime ([@c74]). In the present study, a larger number of cells was observed in iWAT, and one could speculate that these rats may be at a higher risk of storing more fat because of the increased number of cells; this could possibly increase the risk for these animals to develop overweight later in life.

Although adipocyte cell density was higher in iWAT samples from female BPA0.5 offspring compared with controls (and BPA50 offspring), there were no significant differences in the expression of any of the genes measured in iWAT in females (data not shown). In males, adipocyte cell density was higher in iWAT samples from BPA50 offspring than from controls (although not significantly so), whereas expression of 2 of the 30 genes measured in iWAT was lower in BPA0.5 and BPA50 offspring than in controls (significant for the BPA0.5 group only). The relationship between the expression of individual genes and adipose tissue development and regulation is complex, and expression at a single point in time may not reflect expression during critical periods of development. However, additional research will be needed to confirm our findings with regard to the effects of developmental BPA exposure on gene regulation and to determine whether there are any longer-term consequences for BW.

Expression of regulatory adipogenesis-related genes enables proliferation and differentiation of preadipocytes into lipid-storing and expanding adipocytes in a given fat depot ([@c18]). In the present study, significant alterations in adipocyte gene expression were observed in BPA-exposed rats. Among these genes were key regulators and enzymes in adipocyte lipogenesis: Both SCD1 and *ACC* are regulated by the transcription factor *SREBP-1c*. The enzyme SCD1 converts dietary fatty acids ([@c46]) and has been described as having an important role in obesity development because mice lacking *SCD1* are obesity-resistant and are more insulin-sensitive ([@c54]). Furthermore, adipose tissue-specific knockout of *ACC*, another central enzyme in lipogenesis, causes a reduction in adipose tissue lipid accumulation ([@c43]). Earlier reports on exposure of adult rodents to BPA demonstrate an impact on lipogenesis in female adipose tissue as well as in the liver in both sexes, where low BPA doses up-regulate SCD1 and *ACC* mRNA and protein ([@c45]; [@c72]). These findings are not consistent with and are opposite to those in the present study, where slightly but significantly reduced SCD1 and *ACC* mRNA levels were observed in male adipose tissue only, with either a low or high BPA dose, which unexpectedly did not correlate with reduced body or adipose tissue weights. This result could indicate that these modest BPA-induced changes on mRNA level do not influence SCD1 and ACC protein levels or function. Furthermore, discrepancies between results in the present study and those in earlier studies might be explained by, for example, differences in strain, species, choice of dose, route of administration, diet, or time of sacrifice. These discrepancies could create problems in risk assessment for chemicals if they are interpreted as inconsistent results; however, given the complexity of hormonal regulation under different circumstances, it is important to consider all available results, particularly those concerning endocrine disruption.

$\text{CEBP}\alpha$, which is the master regulator in hepatocyte maturation ([@c81]), was down-regulated in the BPA50 male rat liver in the present study. A similar down-regulation of the $\text{CEBP}\alpha$ transcription factor was reported to arise in mouse offspring after developmental BPA exposure; however, this occurred only in females ([@c15]). This reduction in $\text{CEBP}\alpha$, indicative of perturbations in hepatocyte development and a putative fetal origin for BPA-induced hepatic disorders, may not necessarily be sex-specific in general; instead, it may reflect a dose-dependent effect, a species-dependent effect, or both. Whether the inconsistency in $\text{CEBP}\alpha$ expression between males and females in the different studies is incidental or reflects differences in study design needs further investigation.

In the present study, liver fat infiltration was not significantly higher in male or female offspring exposed to BPA during development. Earlier experimental studies have shown increased liver fat accumulation following BPA exposure when provoked with high-fat diet or fructose. Liver fat accumulation in male Wistar rat offspring on a high-fat diet was higher in rats developmentally exposed to BPA ($50\;\mu g/{kg}\,\text{BW}/\text{d}$) than in unexposed rats on the same diet ([@c95]), and liver fat infiltration in juvenile female F344 offspring on a 5% fructose diet was higher in rats exposed to BPA than in unexposed rats on the same diet ([@c64]). These results suggest that developmental exposure to BPA might not cause liver fat accumulation *per se*, but that BPA aggravates liver fat accumulation if combined with a high-calorie diet. In addition, the additive effect of a high-calorie diet has also been reported for other tissues. In rats given a high-fat diet, those exposed to BPA had a greater increase in obesity, dyslipidemia, and hyperglycemia (some of the conditions that define metabolic syndrome in humans), as well as in hyperleptinemia, hyperinsulinemia, and glucose intolerance, than unexposed rats on the same diet ([@c94]). Perinatally BPA-exposed male rats on a high-fat diet had higher body weights than male rats with perinatal BPA exposure and a normal diet, suggesting that effects of BPA on obesity may occur only when combined with a high-calorie diet ([@c72]). This finding may explain why developmental BPA exposure was not associated with increased BW in the present study because the rats were not given a high-calorie diet.

In the present study, rat offspring developmentally exposed to an environmentally relevant dose of BPA ($0.5\;\mu g/{kg}\,\text{BW}/\text{d}$ had significantly lower heart weight and HSI than unexposed controls, when data from males and females were combined. In addition, HSI was lower in males exposed to $0.5\;\mu g/{kg}\,\text{BW}/\text{d}$ of BPA than in controls. We and others have reported associations between BPA and the expression of genes regulating angiogenesis, vascular tone, and cardiac structure and function, as well as epigenetic DNA methylation marks and the myocardial proteome ([@c35]; [@c40]; [@c57]). In addition, Patel et al. ([@c58]) reported that adult male mice exposed to $\sim 5\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$ from GD11.5 to 3 or 4 mo of age showed more inflammation and less cardiac tissue repair following an experimental myocardial infarction than unexposed mice, had lower collagen and alpha-smooth muscle actin ($\alpha\text{SMA}$), and showed higher matrix metalloproteinase protein 2 (MMP2) and MMP9 expression than controls ([@c58]). Potential mechanisms are unknown, but our findings and those of previous studies suggest that the myocardium may be a target for BPA.

Adiponectin is an adipocyte-specific secreted protein essential for lipogenesis and adipocyte homeostasis ([@c99]). In contrast with previous reports of lower plasma adiponectin levels in rats with BPA exposure ([@c2]; [@c73]), we found no significant differences in plasma adiponectin levels in BPA-exposed offspring compared with controls (in males, females, or both sexes combined). Although we noted significant differences in the expression of *AdipoR1* and *AdipoR2* in adipose tissue, associations were both positive and negative depending on the specific tissue, the dose, and the sex of the animals. In principle, effects of BPA on adiponectin signaling might contribute to the development of "adiponectin resistance," which may result in an increase in plasma adiponectin levels or a decrease in target-tissue adiponectin receptor levels ([@c33]; [@c84]).

In the present study, there were no significant differences in plasma leptin levels between male or female offspring developmentally exposed to BPA compared with controls. These findings were consistent with one previous study of developmental exposure to BPA in S-D rats ([@c21]), but not with a study that reported significantly lower plasma leptin levels in exposed female (but not male) mice with developmental exposure compared with controls ([@c102]), or with a study that reported significantly higher plasma leptin levels in developmentally exposed Wistar rats on a high-fat diet compared with unexposed controls on the same diet ([@c94]).

Regulation of gene expression is complex, involving many different mechanisms. In most organs and cell types, this process can be prompted by environmental factors such as modulation of epigenetic marks ([@c11]). Multiple lines of evidence from *in vitro* and *in vivo* models have shown that developmental exposure to certain environmental pollutants, including BPA, can lead to epigenetic modifications, which in turn can induce alterations in gene expression that may persist throughout the lifetime ([@c36]; [@c70]). In addition, researchers have observed that epigenetic modifications can be inherited across generations (transgenerational epigenetic inheritance) ([@c25]; [@c98]). A study by Dolinoy et al. ([@c17]) elegantly demonstrates a change in coat color and development of obesity in BPA-exposed mice (decreased methylation), and further, that this effect was negated by exposure to genistein (increased methylation). This finding showed that an EDC and a phytoestrogen can have opposite effects on epigenetic mechanisms and subsequent effects on the phenotype. The decreased methylation observed after BPA exposure gave rise to yellow coat color, diabetes, tumors, and obesity in the adult phenotype ([@c17]). Alterations of gene expression following BPA exposure are often attributed to ER-mediated actions of BPA. However, BPA has been defined as a SERM, which means that BPA can act through several other pathways and can subsequently induce different effects in various cells and tissues ([@c50]). Further, BPA has been shown to activate several other receptors with the potential to affect epigenetic mechanisms, such as the thyroid hormone and androgen receptors ([@c16]; [@c56]).

In the present study, the simultaneous negative regulation of *SCD1*, *AdipoR1*, *AdipoR2*, and *ACC*, which are involved in prolipogenic and adiponectin-mediated antilipogenic events, may reflect skewed adipocyte gene regulation of potential epigenetic nature. Environmentally induced epigenetic changes are becoming increasingly important in understanding the etiology of health and disease; however, whether low-dose exposure to BPA altered the epigenetic landscape of adipogenesis- and lipogenesis-related genes in these young rats requires further investigation.

The results of the present study suggest a difference in susceptibility to BPA exposure between males and females. Sex-specific susceptibility to xenoestrogens may depend greatly on timing of exposure and type of xenoestrogen. Several previous studies have reported sex-specific effects following BPA exposure. For example, UDP-glucuronosyltransferase 2B1 (UGT2B1) expression in the livers of Wistar-Imamichi rats was significantly higher in female rats than in male rats, and in BPA-exposed rats, levels of glucuronidated BPA were significantly higher in liver microsomes from females than from males, whereas serum BPA concentrations were significantly higher in males than in females ([@c80]). These findings suggest that sex-specific differences in BPA metabolism might have contributed to sex-specific differences in outcomes following developmental exposure to different concentrations of BPA in the present study. In another study, McCaffrey and colleagues ([@c47]) demonstrated that perinatal exposure to BPA altered hypothalamic morphology in a sex-specific manner in rat offspring. Further, in S-D rats, developmental BPA exposure ($100\;\mu g/{kg}/\text{d}$) was associated with significant differences in the hepatic expression of a larger number of genes in males than in females, including $\mathit{CEBP}\alpha$, which was significantly lower in males (but not females) compared with controls on PND1 following developmental exposure to BPA ([@c77]); this finding is consistent with the lower hepatic $\mathit{CEBP}\alpha$ expression on PND35 in BPA50 males (but not females) compared with controls that was observed in the present study.

Different strains of rodents display different sensitivity towards endocrine-disrupting substances ([@c28]; [@c32]; [@c97]). The S-D rat strain has traditionally been used in BPA studies but is reported to be less sensitive to estrogenic substances than other rat strains ([@c76]; [@c82]). Blood prolactin levels were higher in BPA-exposed F344 rats than in controls, but this was not the case in S-D rats ([@c75]). Moreover, DNA synthesis in vaginal epithelium was higher in BPA-exposed F344 rats, but not S-D rats, compared with controls ([@c41]). Thus, caution is needed when choosing an animal model for a specific end point, and the F344 rat used in the present study may be more suitable than S-D rats or other animal models for investigating effects of environmentally relevant levels of endocrine-disrupting substances ([@c62]).

Like humans ([@c92]), F344 rats excrete more BPA via the kidneys than S-D rats ([@c71]), further supporting the idea that the use of the F344 rat model is more suitable for predicting effects in humans. In addition, human liver microsomes do not glucuronidate BPA as extensively as immature female rat liver microsomes, which imply that humans may be exposed to a higher burden than the rat for the same dose of BPA ([@c20]).

Conclusions {#s5}
===========

In conclusion, in the present study of F344 rats developmentally exposed to low doses of BPA, we observed significant differences in markers of lipid and adipocyte homeostasis in exposed offspring compared with controls that varied depending on the dose received and on the sex of the offspring. However, a longer-term study is necessary to define potential late-onset effects of BPA exposure on obesity and metabolic health.

Compared with controls, F344 rat offspring exposed to BPA during development had significantly higher plasma triglyceride levels (BPA50 females and BPA0.5 males) and significantly higher adipocyte density (BPA0.5 females, with a nonsignificant increase in BPA50 males). Moreover, mRNA expression of genes central to lipogenesis and adipocyte adiponectin signaling in adipose tissue, mainly in gWAT, and one gene in the liver ($\mathit{CEBP}\alpha$), differed between BPA-exposed offspring compared with controls, depending on sex and dose. Differences in some metabolic parameters were observed in male or female offspring of dams exposed to the lowest, environmentally relevant, dose ($0.5\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$), which is 8--10 times lower than EFSA's current preliminary TDI of $4\;\mu g\,\text{BPA}/{kg}\,\text{BW}/\text{d}$. The results of the present study add to the list of investigations describing effects from BPA exposures at concentrations lower than the present EFSA TDI, suggesting that regulatory agencies should consider lowering the TDI further.
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